FDA lifts a hold on a Novartis hearing loss drug, and tiny GenVec gets a lift
Back in early January, the struggling penny stock biotech GenVec $GNVC posted a notice with the SEC that its partner Novartis had paused their study on a partnered hearing loss drug so the pharma giant could review safety data.
This morning we found out that there was a clinical hold on the early-stage program, which has now been lifted by the FDA. But there’s no explanation for what triggered the hold.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.